RT Journal Article
T1 Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
A1 Kekre, Natasha
A1 Marquez-Malaver, Francisco J
A1 Cabrero, Monica
A1 Piñana, Jl
A1 Esquirol, Albert
A1 Soiffer, Robert J
A1 Caballero, Dolores
A1 Terol, M J
A1 Martino, Rodrigo
A1 Antin, Joseph H
A1 Lopez-Corral, L
A1 Solano, Carlos
A1 Armand, Philippe
A1 Pérez-Simon, Jose A
K1 Allogeneic
K1 Busulfan
K1 Fludarabine
K1 Lymphoma
K1 Melphalan
K1 Reduced-intensity conditioning
K1 Stem cell transplantation
AB There is at present little data to guide the choice of conditioning for patients with lymphoma undergoing reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT). In this study, we compared the outcomes of patients undergoing RIC SCT who received fludarabine and melphalan (FluMel), the standard RIC regimen used by the Spanish Group of Transplantation, and fludarabine and busulfan (FluBu), the standard RIC regimen used by the Dana-Farber Cancer Institute/Brigham and Women's Hospital. We analyzed 136 patients undergoing RIC SCT for lymphoma with either FluBu (n = 61) or FluMel (n = 75) conditioning between 2007 and 2014. Median follow-up was 36 months. The cumulative incidence of grades II to IV acute graft-versus-host disease (GVHD) was 13% with FluBu and 36% with FluMel (P = .002). The cumulative incidence of nonrelapse mortality (NRM) at 1 year was 3.3% with FluBu and 31% with FluMel (P 
YR 2016
FD 2016-07-25
LK http://hdl.handle.net/10668/10311
UL http://hdl.handle.net/10668/10311
LA en
DS RISalud
RD Apr 6, 2025